BPC-157 Explained: Mechanism, Evidence, Risks, and the Human Trial Gap
This educational video by Bioavailable discusses BPC-157 (Body Protection Compound 157), a synthesized pentadecapeptide composed of 15 amino acids, originally derived from gastric protection research. The video explains that BPC-157 is not FDA-approved for any indication, though an FDA advisory committee discussion was scheduled for July 2026 regarding its potential use for ulcerative colitis. The presenter outlines several proposed mechanisms, including modulation of VEGFR2 signaling, activation of the AKT pathway, stimulation of eNOS and nitric oxide-related pathways, and promotion of angiogenesis (new blood vessel formation) — all of which could theoretically support tissue repair in tendons and ligaments by improving blood supply to injured areas. The video emphasizes that the majority of supporting evidence comes from preclinical sources — cell studies and rodent models — and that a significant gap exists between animal findings and human clinical trials. The presenter also addresses cancer concerns, noting that while BPC-157's angiogenic properties raise theoretical questions about tumor feeding, a direct causal link to cancer is not established. This is an opinion and explainer video, not a peer-reviewed study.